Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/16—Amides, e.g. hydroxamic acids
  • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7088—Compounds having three or more nucleosides or nucleotides
  • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
  • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/66—Phosphorus compounds
  • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7088—Compounds having three or more nucleosides or nucleotides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

• the subject of the present invention is a method for treating a tumor-affected mammalian by administering to said mammalian an effective amount of defibrotide.
• defibrotide normally identifies a polydeoxyribonucleotide that is obtained by extraction from animal and/or vegetable tissues (1, 2) ; the polydesoxyribo- nucleotide is normally used in the form of an alkali-metal salt, generally a sodium salt, and generally has a molecular weight of about 45- 50 kDa (CAS Registry Number: 83712-60-1) .
• DF is used mainly on account of its antithrombotic activity (3) , although it can be used in other applications such as, for example, the treatment of acute renal insufficiency (4) and the treatment of acute myocardial ischaemia (5) .
• DF is also used in the treatment of emergency clinical conditions, for example, for suppressing the toxicity correlated with high doses of chemotherapy regimens, in particular, the hepatic veno-occlusive syndrome (10, 11) ; DF has been shown to have protective action towards apoptosis induced by fludarabine and towards the alloactivation of endothelial and epithelial cells, without also altering the antileukaemic effects of fludarabine (12); pre-clinical data also exists on the protective effects of DF that have been achieved in a model of endothelial damage mediated by lipopolysaccharide (13) .
• a method of producing DF that can produce a product which has uniform and well-defined physical/chemical characteristics and which is also free of
• DF was examined in combination with antiblastic cytotoxic agents in a model of mouse EMT- ⁇ mammary carcinoma cells and in bovine endothelial cells, in cell cultures and in an experimental model in which rats carrying tumours subjected to high doses of chemotherapy were used.
• EMT-6 cells In particular, exposure of EMT-6 cells to DF before and during exposure to thiotepa increases cytotoxicity towards the tumour cells by two logarithmic units for thiotepa concentrations of between 100 and 250 ⁇ mol.
• An interesting datum which emerges is that the exposure of EMT- ⁇ cells to DF during and after exposure to thiotepa leads to an increase in cytotoxicity, although to a lesser extent, showing an increase of between 0.5 and 1 logarithmic unit in the cytotoxicity of thiotepa.
• hepatotoxin monocrotaline and the AA carmustine (BCNU) were tested in vivo in an experimental model which used rats carrying mammary carcinoma 13762.
• BCNU AA carmustine
• no additional toxicity was shown in the animals when they were exposed to these agents together with DF, but a significant tumour growth delay (TGD) was observed (see Table 1 and Figures 2a and 2b) .
• Table 1 Tumour growth delay in rats carrying mammary carcinoma 13762 after treatment with monocrotaline or BCNU, alone or in association with defibrotide (DF) .
• the tumour was implanted on day 0 and the chemotherapy was administered on day 8 and day 18.
• mice Sixty male SCID/NOD mice (6-8 weeks old) were irradiated (450 rads) and, 24 hrs later, injected s.c. with 5x10 6 MM- 1S human MM cells. Upon formation of palpable tumors, mice were randomly assigned to 6 cohorts (10 mice each) receiving a) vehicle; b) DF (i.v. 450 mg/kg b.i.d); c) melphalan (MEL) 2.5 mg/kg i.p.
• MEL melphalan
• DF cyclophosphamide
• Mice were monitored q3 days for body weight, potential toxicity, and electronic caliper-based tumor volumes.
• DF either as single agent or in combination with MEL or CTX, was well tolerated without hemorrhagic complications or body weight loss (P>0.05) in all groups.
• the major endpoints for efficacy were a) tumor volume changes and b) overall survival (time-to- sacrifice, performed when tumor diameters > 2 cm) .
• DF treatment resulted in significantly lower tumor volumes than in control mice (P ⁇ 0.05 for all comparisons by analysis of variance and post-hoc tests) ; in combination with MEL or CTX it induced significantly lower tumor volumes than the respective single-agent cytotoxic chemotherapy (P ⁇ 0.05 for all comparisons).
• Kaplan-Meier survival analyses showed that DF administration, either as single agent or in combination with cytotoxic chemotherapy (MEL or CTX) , was associated with statistically significant prolongation of overall survival, in comparison to vehicle-treated control group or MEL- or CTX-treated groups, respectively (P ⁇ 0.001 for all comparisons, log- rank test) .
• the in vitro studies have not shown a significant direct in vitro cytotoxic effect of DF against MM cells, suggesting that the observed in vivo activity may be due to effect (s) on interactions of MM cells with their local microenvironment .
• a method for treating a tumor-affected mammalian, preferably a human, by administration of an effective amount of DF is therefore an object of the present invention.
• DF may be administered in combination with at least another active ingredient with anti-tumour action.
• the other active ingredient with anti-tumour action may be selected from paclitaxel, monocrotaline, BCNU, melphalan and/or cyclophosphamide.
• the formulations containing DF and at least one other active ingredient with anti-tumour action are represented by the formulations containing DF and at least one other active ingredient with anti-tumour action; the formulations will preferably be in the form of aqueous solutions and, even more preferably, suitable for intravenous administration, and may contain the excipients and coadjuvants known in the art.
• the term defibrotide (DF) should thus be understood as any oligonucleotide and/or polynucleotide produced by extraction from animal and/or vegetable tissues, in particular, from mammalian organs.
• the DF will be produced in accordance with the method described in United States patents (6, 7) which are incorporated herein by reference.
• CAM-DR cell adhesion mediated drug resistance
• Defibrotide reduces procoagulant activity and increases fibrinolytic properties of endothelial cells. Leukemia, 2003; in press.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Epidemiology (AREA)
• Molecular Biology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Biochemistry (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Priority Applications (15)

Applications Claiming Priority (4)

Related Child Applications (1)

Publications (1)

Family

ID=37064585

Family Applications (1)

Country Status (23)

Cited By (6)

Families Citing this family (6)

Citations (5)

Family Cites Families (26)

• 2003
  • 2003-09-05 IT IT001714A patent/ITMI20031714A1/it unknown
• 2004
  • 2004-08-27 ES ES04764686T patent/ES2308223T3/es not_active Expired - Lifetime
  • 2004-08-27 KR KR1020067004451A patent/KR20060061367A/ko not_active Withdrawn
  • 2004-08-27 EP EP04764686A patent/EP1660100B1/en not_active Expired - Lifetime
  • 2004-08-27 CA CA2537226A patent/CA2537226C/en not_active Expired - Fee Related
  • 2004-08-27 CN CNB2004800253315A patent/CN100490820C/zh not_active Expired - Fee Related
  • 2004-08-27 MX MXPA06002489A patent/MXPA06002489A/es active IP Right Grant
  • 2004-08-27 ZA ZA200601852A patent/ZA200601852B/en unknown
  • 2004-08-27 WO PCT/EP2004/009723 patent/WO2005023273A1/en not_active Ceased
  • 2004-08-27 UA UAA200602374A patent/UA83500C2/uk unknown
  • 2004-08-27 RS YUP-2006/0154A patent/RS20060154A/sr unknown
  • 2004-08-27 JP JP2006525096A patent/JP4671962B2/ja not_active Expired - Fee Related
  • 2004-08-27 AT AT04764686T patent/ATE399558T1/de active
  • 2004-08-27 RU RU2006109210/15A patent/RU2348413C2/ru not_active IP Right Cessation
  • 2004-08-27 BR BRPI0414114-8A patent/BRPI0414114A/pt not_active IP Right Cessation
  • 2004-08-27 AU AU2004269896A patent/AU2004269896B2/en not_active Ceased
  • 2004-08-27 PT PT04764686T patent/PT1660100E/pt unknown
  • 2004-08-27 DE DE602004014787T patent/DE602004014787D1/de not_active Expired - Lifetime
  • 2004-08-27 DK DK04764686T patent/DK1660100T3/da active
• 2006
  • 2006-02-16 IL IL173785A patent/IL173785A0/en unknown
  • 2006-02-28 IS IS8334A patent/IS8334A/is unknown
  • 2006-03-02 US US11/366,243 patent/US8551967B2/en not_active Expired - Fee Related
  • 2006-03-28 NO NO20061402A patent/NO20061402L/no not_active Application Discontinuation
• 2013
  • 2013-09-06 US US14/019,674 patent/US20140005256A1/en not_active Abandoned

Patent Citations (5)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events